Market Report, "Brazil Pharmaceuticals & Healthcare Report Q1 2011", published

Jan. 24, 2011 - PRLog -- Brazil's recovery from the global crisis continues unabated, boosted by easy access to credit at home and continued strong external demand for its exports. In Q111, the key factors that will drive the country's growth will be the domestic consumer, surging investment and a better-than-anticipated outlook for exports. For 2010 and 2011, while our long-held view for a slowdown in Brazil in H210 is firmly in play as leading indicator data shows growth consolidating, we believe that the drop in economic activity will not be sufficient to bring real GDP growth rates down to our previous forecasts, and are revising up our projections for both 2010 and 2011 to 7.2% and 4.5% respectively (from 6.0% and 3.6% previously).

BMI's average Business Environment Rating for the 17 Americas markets has moved up from 48.6 to 49.0. Brazil maintained a composite pharmaceutical rating of 63.2, remaining fourth in the Americas rank matrix. On a global basis, Brazil has risen through the ranks to 16th position, overtaking China, which previously had equal score but has now dropped to 21st position among the top-scoring emerging markets. As a region, the Americas rank second only behind Western Europe in terms of attractiveness to multinational drugmakers.

Sales of pharmaceuticals in Brazil have expanded strongly in recent years, with annual growth registered at 8.86%, 9.11% and 9.90% in 2007, 2008 and 2009 respectively. The rising growth rates highlight the sector's strong potential and resilience to the recent global economic downturn. BMI forecasts pharmaceutical sales to reach BRL36.180bn (US$20.44bn) in 2010, making Brazil the tenth-largest market globally.

Prescription and OTC drug sales performance should reflect overall market trends due to the lack of reimbursement mechanisms and high reliance on out-of-pocket spending. In 2011, growth in terms of sales volumes is likely to decrease slightly due to increased levels of inflation leading to higher prices. Nevertheless, the growth of a burgeoning middle-class and an ageing population will sustain consumer spending in the medium and long-term. BMI expects the prescription drug market to reach a value of around BRL38.68bn (US$23.66bn) by 2014.

Brazil's generic medicine sector is the largest in Latin America, and is expected to grow to BRL6.26bn (US$3.54bn) by the end of 2010, after another year of strong gains. BMI forecasts generic drug sales will grow at a US dollar CAGR of 19.02% though 2019, while the patented drug market, forecast to reach BRL21.02bn (US$11.88bn) in 2010, will grow at a US dollar CAGR of 10.66% through the ten year period.

Competition in the domestic arena is set to intensify due to Brazil's current industrial policy, which has a strong focus on developing domestically owned pharmaceutical manufacturers in the private sector. The key programme is the PROFARMA initiative, operated by the Brazilian Development Bank (BNDES) and with a budget of BRL3.0bn (US$1.5bn) through 2012. The programme has the expressed aim of creating a small number of globally competitive pharmaceutical producers, reducing the country's large pharmaceutical trade deficits, which will ultimately make market entry for foreign drugmakers less straightforward.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/110291_brazil_pharmaceuticals_...


Partial Table of Contents:

Executive Summary
SWOT Analysis
- Brazil Pharmaceuticals And Healthcare Industry SWOT
- Brazil Political SWOT
- Brazil Economic SWOT
- Brazil Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Americas Pharmaceutical Business Environment Ratings, Q111
- Rewards
- Risks
Brazil - Market Summary
Regulatory Regime
- Intellectual Property Environment
- Counterfeits
- Regulator Interference
- Compulsory Licensing
- Pricing and Reimbursement Issues
- Tax Burden on Pharmaceuticals
- OTC Regulations
- Advertising
- Other Regulatory Developments
Industry Developments
- Epidemiology
- Healthcare Sector
- PROFARMA Initiative
- Research and Development
- Clinical Trials
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2006-2014
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Trends, Historical Data and Forecasts, 2006-2014
- Key Growth Factors - Macroeconomic
- Table: Brazil - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2006-2014
- Patented Drug Market Forecast
- Table: Patented Drug Sales Indicators 2006-2014
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2006-2014
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2006- 2014
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Imports & Exports Indicators 2006-2014
- Table: Pharmaceutical Imports & Exports Indicators 2006-2014
- Medical Device Market Forecast
- Table: Medical Device Sales Indicators 2006-2014
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Top 20 Pharmaceutical And Healthcare Companies In Brazil By Revenues 2009
- Innovative Drugmakers
- Innovative Drugmakers - Quarterly Developments
- Generic Drugmakers
- Generic Drugmakers - Quarterly Developments
- OTC Sector
- Distribution Sector
- Retail Market - Recent Developments
Company Monitor
- Ache/Biosintetica
- EMS Sigma
- Eurofarma
- Medley
- Cristalia
- Sanofi-Aventis
- Pfizer
- Merck and Co
- Novartis
- GlaxoSmithKline (GSK)
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1102...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.